Green Tea Extract Studied for Breast Cancer Prevention in High-Density Postmenopausal Women
Background
Risk of breast cancer is significantly influenced by factors like mammographic density, a known independent predictor. Current pharmacological prevention strategies for high-risk postmenopausal women, such as tamoxifen, can have notable side effects. Green tea extract, rich in catechins, is hypothesized to offer a natural alternative by modulating pathways involved in estrogen metabolism and insulin-like growth factor 1 (IGF-1), potentially reducing breast cancer risk.
Study Design
This Phase II trial is designed to evaluate the efficacy of green tea extract compared to a placebo in postmenopausal women with high breast density for breast cancer prevention. The study specifically hypothesizes that the preventative effect of green tea will be most pronounced in women with a low-activity COMT genotype. Investigators will assess effects on various breast cancer biomarkers, including mammographic density, plasma IGF-1, IGFBP-3, estrone, estradiol, androstenedione, SHBG, urinary estrogen metabolites, and plasma F2-isoprostanes.
Why It Matters
Identifying natural, well-tolerated agents for breast cancer prevention is crucial, especially for high-risk postmenopausal women seeking alternatives to pharmaceutical interventions. If green tea extract demonstrates significant positive changes in breast cancer biomarkers, it could pave the way for a non-pharmacological strategy to reduce breast cancer incidence, potentially complementing or providing an alternative to existing therapies like tamoxifen. The investigation into the COMT genotype suggests a future for personalized prevention, where genetic profiling could identify individuals most likely to benefit from specific dietary or supplemental interventions, optimizing public health recommendations.
green tea
breast cancer
prevention
postmenopausal
phase ii trial
biomarkers